Recombinant Human Tyrosine-Protein Kinase Btk (BTK)
Beta LifeScience
SKU/CAT #: BLC-07560P
Greater than 90% as determined by SDS-PAGE.
Recombinant Human Tyrosine-Protein Kinase Btk (BTK)
Beta LifeScience
SKU/CAT #: BLC-07560P
Regular price
$58500
$585.00
Sale price$34900
$349.00Save $236
/
Submit an inquiry or email sales for a custom bulk quote. Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Connect with us via the live chat in the bottom corner to receive immediate assistance.
Product Overview
| Description | Recombinant Human Tyrosine-Protein Kinase Btk (BTK) is produced by our E.coli expression system. This is a protein fragment. |
| Purity | Greater than 90% as determined by SDS-PAGE. |
| Uniprotkb | Q06187 |
| Target Symbol | BTK |
| Synonyms | (Agammaglobulinemia tyrosine kinase)(ATK)(B-cell progenitor kinase)(BPK)(Bruton tyrosine kinase) |
| Species | Homo sapiens (Human) |
| Expression System | E.coli |
| Tag | Tag-Free |
| Target Protein Sequence | EIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES |
| Expression Range | 396-659aa |
| Protein Length | Partial |
| Mol. Weight | 31.0 kDa |
| Research Area | Immunology |
| Form | Liquid or Lyophilized powder |
| Buffer | Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0. |
| Reconstitution | Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Storage | 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Notes | Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week. |
Target Details
| Target Function | Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members. PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK. BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways. Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway. The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense. Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells. Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation. BTK plays also a critical role in transcription regulation. Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes. BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B. Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR. GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression. ARID3A and NFAT are other transcriptional target of BTK. BTK is required for the formation of functional ARID3A DNA-binding complexes. There is however no evidence that BTK itself binds directly to DNA. BTK has a dual role in the regulation of apoptosis. |
| Subcellular Location | Cytoplasm. Cell membrane; Peripheral membrane protein. Nucleus. Note=In steady state, BTK is predominantly cytosolic. Following B-cell receptor (BCR) engagement by antigen, translocates to the plasma membrane through its PH domain. Plasma membrane localization is a critical step in the activation of BTK. A fraction of BTK also shuttles between the nucleus and the cytoplasm, and nuclear export is mediated by the nuclear export receptor CRM1. |
| Protein Families | Protein kinase superfamily, Tyr protein kinase family, TEC subfamily |
| Database References | |
| Associated Diseases | X-linked agammaglobulinemia (XLA); X-linked hypogammaglobulinemia and isolated growth hormone deficiency (XLA-IGHD) |
| Tissue Specificity | Predominantly expressed in B-lymphocytes. |
Gene Functions References
- Btk acts in the TLR7/8 pathway and mediates Ser-536 phosphorylation of p65 RelA and subsequent nuclear entry in primary human macrophages. PMID: 29567473
- Study shows that high BTK expression predicts poor outcome in patients with glioma. Its overexpression is required for EGFR-induced NF-kappaB activation. PMID: 28946903
- The Btk-dependent PIP5K1gamma lipid kinase activation by Fas counteracts FasL-induced cell death. PMID: 28879546
- Study utilized bone biopsies from patients with metastatic multiple myeloma and demonstrated that tyrosine phosphorylation by Bruton kinase may be a key disease event: Bruton kinase remained translocated to the membrane; upregulation of transcripts of several factors like activins A; increased expression of numerous cytokines that support osteolytic activity. PMID: 29480835
- BTK-inhibitor ibrutinib and FK866 resulted in a significant and synergistic anti-Waldenstrom macroglobulinemia cell death, regardless of MYD88 and CXCR4 mutational status. PMID: 27287071
- Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The data were confirmed in an in vivo experiment treating DLBCL xenografts with pimasertib and ibrutinib. PMID: 26961147
- these data show that BTK is a critical NLRP3 inflammasome regulator PMID: 28216434
- Resistant BTK mutants reconstituted B cell receptor-triggered chemokine secretion in the presence of corresponding inhibitors, demonstrating that BTK activity is connected with cell-intrinsic functions of malignant B cells with importance for their dialogue with the micro-environment. PMID: 28573668
- Bone marrow mesenchymal stem cells could increase myeloma stemness via activation of the BTK signal pathway. PMID: 28273548
- the results show that the interaction between BTK and ANKRD54 is highly selective, since it was also identified in a screen using human SH3-domainome. A novel finding is that BTK not only binds to ANKRD54, but stands out as the preferred interactor, being highly dominant over all other human SH3-domains. PMID: 28369144
- BTK, via p65BTK expression, is a novel and powerful oncogene acting downstream of the RAS/MAPK pathway and suggest that its targeting may be a promising therapeutic approach. PMID: 26804170
- We conclude that despite being involved in oncogenic signals in blood malignancies, BTK has antineoplastic properties in other contexts, such as the enhancement of p53's tumor suppressor responses PMID: 27630139
- Inhibition of Btk by inhalation of aerosolized RN983 may be effective as a stand-alone asthma therapy. PMID: 27111445
- LMP2A signaling results in STAT3 phosphorylation in B cells through a PI3K/BTK-dependent pathway. PMID: 27792904
- Case Report: Btk mutation responsible for X-Linked agammaglobulinemia manifesting as Pseudomonas aeruginosa liver abscess. PMID: 28398200
- this review describes contributions of BTK to immune tolerance, including studies testing BTK-inhibitors for treatment of autoimmune diseases PMID: 26864273
- The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin. PMID: 28422989
- report that BTK is expressed by murine and human MDSCs, and that ibrutinib is able to inhibit BTK phosphorylation in these cells PMID: 26880800
- Novel BTK mutations have been described in a large cohort of North African patients with X-Linked agammagobulinemia. PMID: 26931785
- mutational analysis in cohort of Iranian patients with congenital agammaglobulinemia PMID: 26910880
- We report that BTK regulates B-cell and macrophage-mediated T-cell suppression in pancreas adenocarcinomas. PMID: 26715645
- Data show that Bruton tyrosine kinase (BTK)inhibitor Ibrutinib augments MALT lymphoma associated translocation protein (MALT1) inhibition by S-Mepazine in CD79 antigen mutant activated B cell-subtype (ABC) of diffuse large B cell lymphoma (DLBCL). PMID: 26540570
- BTK-C is a survival factor in prostate cancer cells. PMID: 26383180
- BTK RNA interference inhibits proliferation of FLT3-ITD acute myeloid leukemia cells. PMID: 26292723
- Activates PKC independent of BTK. PMID: 26089373
- study investigated all single-nucleotide substitution-caused amino acid variations in the kinase domain of Bruton tyrosine kinase; most disease-causing variations affect conserved and buried residues disturbing protein stability; sixty-seven percent of variations are predicted to be harmful PMID: 25777788
- Data show that Bruton tyrosine kinase (Btk) inhibitor PLS-123 suggested a new direction to pharmacologically modulate Btk function and develop novel therapeutic drug for B-cell lymphoma treatment. PMID: 25944695
- FcgammaRIIB requires Btk and p38 MAPK to mediate antigen-independent inhibition in human B cells. PMID: 26475492
- We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer. PMID: 26036311
- Letter: report BTK inhibitor ibrutinib induced panniculitis in lymphoid leukemia patients. PMID: 26182170
- study indicates that BTK is essential for NLRP3 inflammasome activation and could be a potent therapeutic target in ischaemic stroke PMID: 26059659
- Data indicate that the X linked agammaglobulinemia (XLA) diagnosis was confirmed for six patients with six different mutations. PMID: 26387629
- The immunoglobulin tail tyrosine motif in the cytoplasmic segments of membrane-bound IgGs acts as the principle signal amplifier by incorporating a Grb2-Btk signaling. PMID: 25413232
- Btk not only plays a fundamental role in the regulation of BCR signalling, but may also mediate crosstalk with cytokine signalling pathways through regulation of IL-21-induced phosphorylation of STAT1 in the nuclei of human B cells. PMID: 25724205
- The BTK missense mutation resulted in B cells with reduced BTK and high IgM expression. PMID: 25589397
- BTK is involved in determining proliferative, quiescent or metastatic phenotypes of myeloma cells. PMID: 25083818
- report of a case in a male with variant form of X-linked agammaglobulinemia (XLA) with partial B cell function that results from a missense mutation (c.1117C > G) in exon 13 of the BTK gene; four female carriers were found in the family PMID: 25316352
- miR-155 affects chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib PMID: 25486872
- BTK is a positive regulator of myeloma stemness PMID: 25589346
- Cysteine 481 to serine BTK mutation confers ibrutinib resistance of chronic lymphocytic leukemia cells. PMID: 25189416
- FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation PMID: 25605370
- Data indicate that dual inhibition of Brutons tyrosine kinase (BTK) and mTOR serine-threonine kinases as a potential treatment for ABC-subtype diffuse large B cell lymphoma. PMID: 24970801
- Docking and physicochemical studies indicated that BTK was involved in close contact with Tyr86 and Tyr106 of MAL, whereas PKCdelta may phosphorylate Tyr106 only. PMID: 24840642
- X-linked agammaglobulinemia is reported in two siblings with a novel mutation in the BTK gene. They presented with polyarticular juvenile idiopathic arthritis. PMID: 25757060
- Data indicate RN486 as potent and selective Bruton's tyrosine kinase (BTK) inhibitor and potential treatments for Rheumatoid arthritis. PMID: 24712864
- we report the pattern of expression of Btk in a large collection of different types of lymphoma. PMID: 25433814
- Data indicate that ibrutinib-resistant Bruton tyrosine kinase (BTK) mutation is one of the genetic causes of ibrutinib resistance in chronic lymphocytic leukemia (CLL). PMID: 25498455
- Unfolded protein response activation following surface immunoglobulin M stimulation in vitro is dependent on the activity of BTK and SYK. PMID: 25170122
- We observed that Nef interacts with the Tec family members Bmx, Btk, and Itk but not Tec or Txk. PMID: 24722985
- These results suggest that the function of BTK warrants further investigation, and BTK expression might be used as a prognostic indicator for patients with MM. PMID: 23581641
